Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline

Servier announced today that it has entered into a definitive agreement with the owners of Symphogen A/S, a leader in therapeutic antibody discovery, to acquire 100% of Symphogen’s share capital. The acquisition, the result of a process that has been underway for several months now, will strengthen Servier’s antibody capabilities and ensure that Symphogen’s antibody discovery and early-development platform is fully utilized.

Under the terms of the agreement, Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.

Following completion of the acquisition, Symphogen will become Servier’s antibody center of excellence for its therapeutic areas. Symphogen will operate as a standalone organization within the Servier Group, maintain its headquarters in Ballerup, Denmark, and continue to rely on its current and experienced employees.